This category covers EnerTherm Engineering’s specialized feasibility study services for the pharmaceutical sector, focusing on the technical, regulatory, and financial viability of new facility investments and existing site modifications. Content in this category should address the end-to-end project lifecycle, from initial consultation to implementation planning, specifically for API, formulation, biologics, and fill-finish facilities. Key topics include cleanroom facility planning (HVAC capacity, contamination control, ISO 14644, and GMP Annex 1 compliance), utility infrastructure analysis (WFI, clean steam, compressed air), and GMP gap analysis against FDA 21 CFR and EU GMP requirements. Articles should highlight EnerTherm’s 6-step methodology, which utilizes advanced technical processes such as Industrial Process Modelling, Pinch Analysis, CAE simulation, CFD studies, and statistically designed experiments. Content should also emphasize the firm’s approach to financial transparency, including CAPEX/OPEX estimation, ROI projections, and the integration of preliminary validation strategies (IQ/OQ/PQ) into the early design phase. Authors should focus on how these studies mitigate regulatory risks, prevent costly redesigns, and accelerate project timelines, while referencing technical standards like ICH guidelines and regulatory requirements from the FDA and EMA. Posts should be grounded in the firm’s performance metrics, such as achieving 100% GMP compliance, 6-month timeline acceleration, and 20% design cost savings.